Kalshi Sells 75% of $1.5B Equity Round at $1.12B
71 investors back the CFTC-regulated prediction exchange in a Reg D private offering still $380M short of its target.
Kalshi has sold $1.12 billion of its $1.5 billion equity offering — roughly 75 percent — across 71 investors, according to a Form D filing reported by CoinTelegraph on August 26, 2026.
Why It Matters
The raise signals sustained institutional appetite for regulated prediction market infrastructure even as the broader crypto funding environment remains uneven. Kalshi is relying on a Regulation D exemption, meaning the offering bypasses full SEC registration — a legal pathway that allows faster capital deployment but limits participation to accredited investors. For the prediction markets sector, a capitalisation round at this scale validates the space as a serious financial category, not a speculative curiosity. The remaining $380 million in unfilled allocation also suggests Kalshi is selectively choosing counterparties rather than scrambling to close.
Context
Kalshi holds a Commodity Futures Trading Commission (CFTC) designation as a regulated event contract market, distinguishing it from offshore or grey-market prediction platforms. The company rose to prominence after winning a legal battle that cleared it to offer political event contracts in the United States. That regulatory clarity has made it a focal point for investors seeking exposure to prediction markets through a compliant structure.
What's Next
Kalshi must close the remaining roughly $380 million or file an amendment to its Form D disclosing final terms. How the company deploys this capital — product expansion, regulatory lobbying, or international licensing — will be the next meaningful signal for the sector.
Gambling and prediction market participation involves financial risk. Always review applicable regulations in your jurisdiction.
Related on WeeBet
Keep reading
WeeBet Weekly
The week's biggest market move, in 4 minutes.
Every Friday: the top Polymarket and Kalshi price shift, one regulatory story that actually matters, and one chart. No fluff, no promo. Free.
Free. Unsubscribe in one click. We'll never sell your email.